Interleukin 2-Based Fusion Proteins for the Treatment of Cancer

Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alana MacDonald, T.-C. Wu, Chien-Fu Hung
Formato:	article
Lenguaje:	EN
Publicado:	Hindawi Limited 2021
Materias:	Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/fb172ce1ca654f948f000f3fe9370909
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb172ce1ca654f948f000f3fe9370909
record_format	dspace
spelling	oai:doaj.org-article:fb172ce1ca654f948f000f3fe93709092021-11-22T01:09:41ZInterleukin 2-Based Fusion Proteins for the Treatment of Cancer2314-715610.1155/2021/7855808https://doaj.org/article/fb172ce1ca654f948f000f3fe93709092021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/7855808https://doaj.org/toc/2314-7156Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. Over the past three decades, efforts have focused on circumventing IL-2-related toxicities by engineering methods to localize IL-2 to the tumor or secondary lymphoid tissue, preferentially activate CD8+ T cells and NK cells, and alter pharmacokinetic properties to increase bioavailability. This review summarizes the various IL-2-based strategies that have emerged, with a focus on chimeric fusion methods.Alana MacDonaldT.-C. WuChien-Fu HungHindawi LimitedarticleImmunologic diseases. AllergyRC581-607ENJournal of Immunology Research, Vol 2021 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607
spellingShingle	Immunologic diseases. Allergy RC581-607 Alana MacDonald T.-C. Wu Chien-Fu Hung Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
description	Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. Over the past three decades, efforts have focused on circumventing IL-2-related toxicities by engineering methods to localize IL-2 to the tumor or secondary lymphoid tissue, preferentially activate CD8+ T cells and NK cells, and alter pharmacokinetic properties to increase bioavailability. This review summarizes the various IL-2-based strategies that have emerged, with a focus on chimeric fusion methods.
format	article
author	Alana MacDonald T.-C. Wu Chien-Fu Hung
author_facet	Alana MacDonald T.-C. Wu Chien-Fu Hung
author_sort	Alana MacDonald
title	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
title_short	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
title_full	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
title_fullStr	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
title_full_unstemmed	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
title_sort	interleukin 2-based fusion proteins for the treatment of cancer
publisher	Hindawi Limited
publishDate	2021
url	https://doaj.org/article/fb172ce1ca654f948f000f3fe9370909
work_keys_str_mv	AT alanamacdonald interleukin2basedfusionproteinsforthetreatmentofcancer AT tcwu interleukin2basedfusionproteinsforthetreatmentofcancer AT chienfuhung interleukin2basedfusionproteinsforthetreatmentofcancer
_version_	1718418437970067456

Interleukin 2-Based Fusion Proteins for the Treatment of Cancer

Ejemplares similares